France recently announced a liberalization of its laws governing hemp. The French import and export market for hemp and hemp products is open.
Continue reading “Mieux Vaut Tard Que Jamais- France Approves CBD Sales but Prohibits Hemp Flower”…
The post Mieux Vaut Tard Que Jamais- France Approves CBD Sales but Prohibits Hemp Flower first appeared on Kight on Cannabis.
I am fortunate enough to speak with clients, attorneys, and other experts in the cannabis industry on a daily basis and have some thoughts about what we can expect for cannabis (by which I mean both “hemp” and “marijuana”) in 2002.
Continue reading “Will 2022 Be a Stormy Year for Cannabis? (VIDEO AND ARTICLE)”…
The post Will 2022 Be a Stormy Year for Cannabis? (VIDEO AND ARTICLE) first appeared on Kight on Cannabis.
In this article I argue that products containing hemp extract with delta-9 THC concentrations sufficient to cause intoxication that do not exceed the legal limit of 0.3% on a dry weight basis are not controlled substances under the federal Controlled Substances Act and that attempting to regulate hemp products based on intoxication is a Fool’s Errand.
Continue reading “D9 is the New D8 or: How I Learned to Stop Worrying and Love Intoxicating Hemp”…
The post D9 is the New D8 or: How I Learned to Stop Worrying and Love Intoxicating Hemp first appeared on Kight on Cannabis.
This article discusses the legal status of hemp in Mexico, an evolving issue that was the subject of a recent decision by the country’s highest court. It also makes some predictions and practical recommendations for engaging in the emerging Mexican hemp industry.
Continue reading “Mexico and Hemp: A Strong Emerging Market”…
The post Mexico and Hemp: A Strong Emerging Market first appeared on Kight on Cannabis.
The District Court in Travis County, Texas entered a temporary injunction this morning in our pending lawsuit against the Department of State Health Services (DSHS) regarding its improper scheduling of delta-8 THC from hemp.
Continue reading “Texas Court Enters Injunction Regarding Delta-8 THC”…
The post Texas Court Enters Injunction Regarding Delta-8 THC first appeared on Kight on Cannabis.
Our position on D8 from hemp was recently confirmed by the DEA in two public announcements- a webinar and a letter. See the video and read the letter in this post.
Continue reading “Is D8 From Hemp a Controlled Substance? DEA Says “No”.”…
The post Is D8 From Hemp a Controlled Substance? DEA Says “No”. first appeared on Kight on Cannabis.
With limited exceptions, the USPS will no longer accept or send any package that contains hemp vaping products. Hemp vapes that are deposited in the mail are subject to seizure and forfeiture and senders are subject to criminal fines, imprisonment, and civil penalties.
Continue reading “USPS Will No Longer Mail Hemp Vapes”…
The post USPS Will No Longer Mail Hemp Vapes first appeared on Kight on Cannabis.
Texas joins the ranks of states that have banned hemp-derived delta 8 THC. Its Department of State Health Services quietly placed D8 onto the state’s list of controlled substances following the legislature’s inability to pass a bill that would have banned it.
Continue reading “Whoa partner! A State Agency Quietly Banned Delta-8 in the Lone Star State”…
The post Whoa partner! A State Agency Quietly Banned Delta-8 in the Lone Star State first appeared on Kight on Cannabis.
On October 4, the South Carolina Attorney General (AG) issued an unfavorable opinion regarding the legal status of delta-8 THC at the request of the South Carolina Law Enforcement Division (SLED). In this post we discuss the AG’s flawed analysis and its likely effect.
Continue reading “The Fate of D8 in the Palmetto State: South Carolina AG Addresses Delta 8 THC”…
The post The Fate of D8 in the Palmetto State: South Carolina AG Addresses Delta 8 THC first appeared on Kight on Cannabis.
Rod discusses delta-8 THC, federal legalization, and the future of CBD on the C3 Higher Learning LV podcast with Curt Robbins and Dena Putnam.
Continue reading “Rod Discusses D8, Federal Legalization, and the Future of CBD on the C3 Podcast (Video)”…
The post Rod Discusses D8, Federal Legalization, and the Future of CBD on the C3 Podcast (Video) first appeared on Kight on Cannabis.
Marijuana impairs a driver’s reaction time, decision-making ability, capacity to accurately track objects, balance and equilibrium. Still, it is difficult to measure when a person is impaired. The intoxicating ingredient in cannabis, tetrahydrocannabinol (THC), is metabolized differently by individuals and remains in the body long after its psychoactive effects have ceased. Currently, there is no way to reliably measure whether a person who has ingested cannabis an hour earlier is impaired because THC concentration does not correlate well with subjective impairment.
The Pennsylvania Department of Health (DOH) reported that almost $100 million in medical marijuana sales occurred between February 15, 2018, and February 15, 2019, the first full year that medical cannabis was available to Pennsylvania patients. More than $40 million in sales occurred between growers and dispensaries. Pennsylvania does not tax sales to patients, but does tax transactions between growers and dispensaries at a rate of 5%. Thus, in the first year of licensed sales, the Commonwealth received approximately $2 million in tax revenue from medical cannabis.
The 2018 U.S. Farm Bill has opened the gates to industrial hemp farming. Hemp, a crop that has been banned in the United States since 1937, now may be legally grown. While the most popular product of hemp − oils containing cannabidiol (CBD) and other naturally occurring non-psychoactive cannabinoids − are still subject to conflicting federal and state regulations, the plant itself may be grown across the United States.
The Commonwealth of Pennsylvania wants medical researchers to study cannabis at Pennsylvania medical schools, eight of which have been certified as Academic Clinical Research Centers (ACRCs). ACRCs can contract with Clinical Registrants (CRs), entities that the Commonwealth will license to cultivate, package and dispense cannabis for medical research. An entire set of regulations, commonly referred to as “Chapter 20,” has been drafted, redrafted and amended to make medical research of cannabis a reality in the Commonwealth.
On December 18, 2018, the Pennsylvania Department of Health (DOH) issued 23 cannabis dispensary permits (Phase II licenses). Fifty entities have been awarded dispensary licenses, which is the total number allowed under Pennsylvania’s Medical Marijuana Act. Each licensee can operate up to three dispensaries, bringing the total number of possible dispensaries in Pennsylvania to 150.
As the legal status of cannabis evolves, state legislatures are confronted with a difficult moral issue – how should local and state governments treat persons convicted of offenses that are no longer illegal? Below is a discussion of some of the options.
But of course, the “hemp oil” or cannabidiol (CBD) remains illegal under state law. Even if the CBD is locally sourced and sold through a licensed dispensary, edibles are not legal in Pennsylvania. Edibles are presently restricted to underage patients New Jersey. Moreover, Pennsylvania’s Medical Marijuana Act (MMA) strictly prohibits advertising or packaging that appeal to children. Candy-shaped CBD probably runs afoul of the spirit of the MMA.
National legalization of cannabis is now a reality − in Canada and Uruguay. Further south, we are still waiting, our hopes stoked by committed legislators who assure us that changes are coming soon.
The Pennsylvania Commonwealth Court has decided a new case that may have a huge impact on cannabis licensing in the Mid-Atlantic region. The Commonwealth Court hears cases involving state and local government entities and state agencies in Pennsylvania and has heard a number of challenges regarding the administration of the 2016 Medical Marijuana Act (MMA).
On September 21, 2018, the Commonwealth of Pennsylvania certified eight medical schools as Academic Clinical Research Centers (ACRCs). The following schools are now certified by the Commonwealth of Pennsylvania to contract with Clinical Registrants (CRs) to conduct medical research: